MEA Bipolar Disorder Market

Middle East and Africa Bipolar Disorder Market Size (2024 to 2029)

The size of the Bipolar Disorder Market in the Middle East and Africa is forecasted to grow at a sluggish rate from 2023 to 2028.

Bipolar disorder is becoming more common as a result of several risk factors such as high stress, substance addiction, and others.

The increasing incidence of bipolar disease, increased government attempts to raise awareness, and technology improvements are a few of the key factors driving the bipolar disorder market forward in MEA. Technology advancements are also assisting the market expansion, as the usage of smartphones, smartwatches, and wearable devices allows for accurate detection of a patient's emotional and mental state, as well as effective capture of physiological, behavioral, and environmental data. Men and women have identical chances of being afflicted by bipolar illness. As a result of the rising number of cases of the disease and the growing need to properly manage them, the MEA bipolar disorder market has grown. The National Institute of Mental Health (NIMH) financed the establishment of the Bipolar Disorder Phenome Database, which provides comprehensive information on the indications and symptoms of the disorder. This element has also contributed to the market's expansion.

However, side effects associated with medications used to treat bipolar illness are projected to be a factor limiting market growth to some extent, as patients are hesitant to seek medication therapy for fear of experiencing the same. Additionally, the market's expansion is hampered by issues such as strict regulatory frameworks, anticonvulsant side effects, and a limited number of licensed anticonvulsants.

This research report on the MEA bipolar disorder market has been segmented and sub-segmented into the following categories.

By Type

• Bipolar I Disorder
• Bipolar II Disorder
• Cyclothymic Disorder

By Mechanism of Action

• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressants
• Benzodiazepines
• Serotonin-norepinephrine Reuptake Inhibitors
• Beta-Blockers
• Selective Serotonin Reuptake Inhibitors
• Others

By Drug Class

• Antianxiety Drugs
• Mood Stabilizers
• Antidepressant Drugs
• Antipsychotic Drugs
• Anticonvulsants

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, Middle East and Africa had a moderate share of the worldwide market in 2020 and are likely to maintain this trend over the forecast period, with no noteworthy deviations. Due to improved knowledge and a wider range of treatment choices, the Middle East and Africa have a moderate share of the worldwide bipolar disorder market. In terms of revenue, the UAE has a large market share in the region, followed by Kuwait.

With developing countries such as the United Arab Emirates and Kuwait, the Middle East and Africa is expected to do well during the forecast period. Increased awareness of the ailment in countries such as the United Arab Emirates is expected to support the growth rate of this regional market.

KEY MARKET PLAYERS

Companies playing a leading role in the MEA bipolar disorder market profiled in this report are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc.